Epilepsy-intellectual disability in females

Zogenix to Participate in Two Upcoming Investor Conferences

Retrieved on:

Monday, June 21, 2021

Health, Clinical medicine, Syndromes, Epilepsy, Dravet syndrome, CDKL5, Lennox–Gastaut syndrome, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

Stephen J. Farr, Ph.D., President and Chief Executive Officer andMichael Smith, Executive Vice President and Chief Financial Officer
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

Retrieved on:

Tuesday, May 11, 2021

Neurological disorders, Health, Clinical medicine, Epilepsy, Dravet syndrome, CDKL5, Lennox–Gastaut syndrome, Syndromes, Fenfluramine, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The company\xe2\x80\x99s first rare disease therapy, FINTEPLA\xc2\xae (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.\n'

Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6

Retrieved on:

Thursday, April 22, 2021

Key Points:

b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The company\xe2\x80\x99s first rare disease therapy, FINTEPLA\xc2\xae (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.\n'

Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference

Retrieved on:

Thursday, April 8, 2021

Health, Neurological disorders, Clinical medicine, Epilepsy, Syndromes, Dravet syndrome, Lennox–Gastaut syndrome, Fenfluramine, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Retrieved on:

Wednesday, March 3, 2021

Key Points:

Under the new exclusive agreement, all global rights to soticlestat have been secured by Takeda from Ovid.
Ovid led global development of soticlestat through the successful demonstration of proof-of-concept in multiple rare epilepsies.
Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021.
Dravet syndrome and Lennox-Gastaut syndrome are types of developmental and epileptic encephalopathies (DEEs), a heterogeneous group of rare epilepsy syndromes.

Zogenix to Participate in the Raymond James Institutional Investors Conference

Retrieved on:

Tuesday, March 2, 2021

Health, Neurological disorders, Clinical medicine, Epilepsy, Syndromes, Dravet syndrome, Lennox–Gastaut syndrome, Fenfluramine, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on:

Thursday, February 18, 2021

Health, Clinical medicine, Medicine, Epilepsy, Syndromes, Neurological disorders, Dravet syndrome, Lennox–Gastaut syndrome, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency (being developed through its subsidiary Modis Therapeutics).
Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.

Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25

Retrieved on:

Thursday, February 11, 2021

Health, Clinical medicine, Neurological disorders, Epilepsy, Syndromes, Dravet syndrome, Lennox–Gastaut syndrome, Fenfluramine, Epilepsy-intellectual disability in females, Epilepsy syndromes

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic mitochondrial depletion disorder called TK2 deficiency.
Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.

Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference

Retrieved on:

Wednesday, November 11, 2020

Health, Clinical medicine, Epilepsy, Syndromes, Neurological disorders, Lennox–Gastaut syndrome, Dravet syndrome, Fenfluramine, Seizure, Epilepsy syndromes, Epilepsy-intellectual disability in females

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.
MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9

Retrieved on:

Thursday, October 29, 2020

Health, Neurological disorders, Clinical medicine, Syndromes, Lennox–Gastaut syndrome, Dravet syndrome, Epilepsy, Fenfluramine, Epileptic seizure, Epilepsy syndromes, Epilepsy-intellectual disability in females

Key Points:

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.
MT1621 is being developed through Modis Therapeutics, a Zogenix company.